Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study-Reference-Cited by-同舟云学术

Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study

Published:2017-12-06 Issue:4 Volume:20 Page:411-415
ISSN:1875-8592
Container-title:Cancer Biomarkers
language:
Short-container-title:CBM

Author:

Deng Wen¹¹,Meng Zimin²¹,Sun Aitao³,Yang Zhihong³

Affiliation:

1. Department of Cardiovascular Medicine, Yantaishan Hospital, Yantai 264000, Shandong, China

2. Department of Cardiovascular Medicine, Weihai Municipal Hospital, Weihai 264200, Shandong, China

3. Department of Digestive, Yantaishan Hospital, Yantai 264000, Shandong, China

Publisher

IOS Press

Subject

Cancer Research,Genetics,Oncology,General Medicine

Reference29 articles.

1. Non Alcoholic Fatty Liver Disease Study and Lonardo Group, et al., Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups, Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 47 (2015), 997–1006.

2. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

3. Epidemiology and natural history of non-alcoholic fatty liver disease;Fazel;Metabolism: Clinical and Experimental,2016

4. The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans;Ballestri;Advances in Therapy,2016

5. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis;Rinaldi;World Journal of Gastroenterology,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Products in Liver Fibrosis Management: A Five-year Review;Current Medicinal Chemistry;2024-09

2. Effects of pioglitazone and metformin on abdominal adhesion formation in an experimental model;Turkish Journal of Trauma and Emergency Surgery;2024

3. Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD);Tissue Barriers;2023-12-05

4. Keeping an eye on the nutrition: The importance of nutrition management on cardiometabolic risk factors in cirrhotic patients;Clinical Nutrition ESPEN;2023-12

5. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review;European Journal of Clinical Pharmacology;2023-11-08